• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Contract Loss Might Change The Case For Investing In EBOS Group Shares

    Simply Wall St·10/16/2026 18:28:53
    语音播报
    • EBOS Group has already endured the loss of its Chemist Warehouse contract and leadership changes, leaving investors focused on how these shifts affect the durability and mix of future earnings across its healthcare and animal care operations.
    • With the share price now broadly aligned to current earnings, the key question for EBOS Group is whether profit quality can keep pace with upcoming logistics upgrades, specialty pharma growth, and ongoing acquisition execution risk.
    • We will now examine how EBOS Group's investment narrative is shaped by lingering concern over the Chemist Warehouse contract loss.

    Broaden your watchlist beyond EBOS Group by scanning our hand-picked list of solid balance sheet and fundamentals (203 results).

    EBOS Group Investment Narrative Recap

    To own EBOS Group, you need to be comfortable with a wholesaler that is reshaping its earnings mix after losing a key Chemist Warehouse contract while still funding heavy logistics upgrades. The short term hinges on whether core healthcare distribution, specialty pharma and software services keep earnings resilient as the share price now roughly mirrors current profit levels.

    The biggest near term swing factor is execution on the distribution center renewal program. This is lifting capital expenditure and finance costs before potential efficiency gains arrive. The main risk is that competitive pressure in pharmacy wholesale and a higher tilt to low margin specialty drugs hold margins down longer than expected.

    Recent commentary has highlighted EBOS Group's multi year distribution center renewal as the clearest operational milestone tied to this reset. Management is pushing through higher automation and capacity. This is increasing depreciation and interest expense today while aiming to support logistics efficiency and service quality once the build out is complete.

    For you as a shareholder, the interest lies in whether these upgraded facilities and specialty pharma capabilities offset margin pressure from pharmacy competition and a higher mix of high value, low margin medicines. Execution on any future bolt on acquisitions adds another layer of risk, since integration outcomes will influence how durable the earnings base looks after the Chemist Warehouse loss.

    EBOS Group's current narrative centers on analysts expecting revenue to reach A$15.3b and earnings of A$288.8m by 2029, based on assumed yearly revenue growth of 4.2% and an earnings increase of about A$63.6m from A$225.2m today.

    Uncover why EBOS Group's fair value indicates a 40% potential upside to its current price, which could narrow quickly.

    NZSE:EBO 1-Year Stock Price Chart
    NZSE:EBO 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on EBOS Group leans heavily on the logistics upgrade as a potential upside swing factor. The most optimistic analysts were pencilling in revenue of about A$15.9b and earnings near A$344.0m by 2029 before this news. That is far above the baseline. Use this news event as a prompt to compare those assumptions with your own and explore how future revisions might reshape the story.

    Explore 4 other EBOS Group fair value estimates, including one that suggests the potential for as much as 120% upside from the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond EBOS Group?

    If the EBOS Group story has sharpened your thinking about risk, cash generation and balance sheet strength, use that same lens to build a wider watchlist with stocks that fit your preferred profile.

    • For investors who want quality at a sensible entry point, scan a curated set of companies that screens for both resilience and valuation support through the 193 high quality undervalued stocks.
    • If income is your focus and you care about consistency as much as yield, zero in on companies aiming to combine robust payouts with defensive characteristics by reviewing the 213 dividend fortresses.
    • For a research list tilted toward financial strength and lower downside risk, filter for businesses with strong balance sheets and dependable fundamentals using the 233 resilient stocks with low risk scores.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.